Safety and pharmacokinetics of anti‐ TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial-Reference-Cited by-同舟云学术

Safety and pharmacokinetics of anti‐ TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

Published:2015-04-06 Issue:5 Volume:13 Page:743-754
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Chowdary P.¹,Lethagen S.²³,Friedrich U.²,Brand B.⁴,Hay C.⁵,Abdul Karim F.⁶,Klamroth R.⁷,Knoebl P.⁸,Laffan M.⁹,Mahlangu J.¹⁰,Miesbach W.¹¹,Dalsgaard Nielsen J.¹²,Martín‐Salces M.¹³,Angchaisuksiri P.¹⁴

Affiliation:

1. Katharine Dormandy Haemophilia Centre and Thrombosis Unit Royal Free Hospital London UK

2. Novo Nordisk A/S Søborg Denmark

3. Copenhagen University Copenhagen Denmark

4. Division of Hematology University Hospital Zurich Switzerland

5. University Department of Haematology Manchester Royal Infirmary Manchester UK

6. Haemophilia Centre National Blood Centre Kuala Lumpur Malaysia

7. Department of Internal Medicine―Angiology, Haemostasis and Coagulation disorders Vivantes Hospital im Friedrichshain Berlin Germany

8. Division of Haematology and Haemostasis Department of Medicine 1 Medical University of Vienna Vienna Austria

9. Imperial College London Hammersmith Hospital London UK

10. Department of Molecular Medicine and Haematology Faculty of Health Sciences University of the Witwatersrand and NHLS Johannesburg South Africa

11. Zentrum für Innere Medizin Med. Klinik III Hämophilie‐Zentrum Frankfurt/M Germany

12. Thrombosis and Haemostasis Unit Department of Haematology Rigshospitalet Copenhagen Denmark

13. Haematology Department Hospital Universitario La Paz Madrid Spain

14. Division of Hematology Department of Medicine Faculty of Medicine Ramathibodi Hospital Bangkok Thailand

Funder

Novo Nordisk A/S, Bagsværd, Denmark

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.12864

Reference24 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B

3. Guidelines for the management of hemophilia

4. Prophylactic therapy in haemophilia

5. Venous access in haemophilic children: choice and management

Cited by 191 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concizumab improves clot formation in hemophilia A under flow;Journal of Thrombosis and Haemostasis;2024-09

2. Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study;Journal of Thrombosis and Haemostasis;2024-09

3. The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference;Patient Preference and Adherence;2024-08

4. Exploring nonreplacement therapies’ impact on hemophilia and other rare bleeding disorders;Research and Practice in Thrombosis and Haemostasis;2024-05

5. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27